Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment.
- Published In:
- Journal of peptide science : an official publication of the European Peptide Society, 31(6), e70016 (2025)
- Database ID:
- RPEP-09761
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-09761APA
Achilleos, Koulla; Petrou, Christos; Nicolaidou, Vicky; Sarigiannis, Yiannis. (2025). Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment.. Journal of peptide science : an official publication of the European Peptide Society, 31(6), e70016. https://doi.org/10.1002/psc.70016
MLA
Achilleos, Koulla, et al. "Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment.." Journal of peptide science : an official publication of the European Peptide Society, 2025. https://doi.org/10.1002/psc.70016
RethinkPeptides
RethinkPeptides Research Database. "Beyond Efficacy: Ensuring Safety in Peptide Therapeutics thr..." RPEP-09761. Retrieved from https://rethinkpeptides.com/research/achilleos-2025-beyond-efficacy-ensuring-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.